Quick Answer
Compass Therapeutics, Inc. reported Operating Income Loss of -$72.84 million for the year ending 2025.
- Compass Therapeutics, Inc. showed a decrease of -28.6% in Operating Income Loss from 2024 to 2025.
- This data is from Compass Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2018 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2018: -$7.9 thousand | Q3 2018: -$7.8 thousand | Q4 2018: -$9.3 thousand | Q2 2019: -$8.67 million | Q3 2019: -$8.38 million | Q4 2019: -$10.2 thousand | Q1 2020: -$5.83 million | Q2 2020: -$5.07 million | Q3 2020: -$8.96 million | Q1 2021: -$7.34 million | Q2 2021: -$55.69 million | Q3 2021: -$5.85 million | Q1 2022: -$7.18 million | Q2 2022: -$8.99 million | Q3 2022: -$12.60 million | Q1 2023: -$9.71 million | Q2 2023: -$13.34 million | Q3 2023: -$11.93 million | Q1 2024: -$12.77 million | Q2 2024: -$15.05 million | Q3 2024: -$12.24 million | Q1 2025: -$17.97 million | Q2 2025: -$21.07 million | Q3 2025: -$15.82 million.
- Over the full 10 years of available data (2018 to 2025), Compass Therapeutics, Inc.'s Operating Income Loss has declined by 208,011.4%.
- Historical annual values: Fiscal year 2025: -$72.84 million | Fiscal year 2024: -$56.63 million | Fiscal year 2023: -$50.36 million | Fiscal year 2022: -$41.66 million | Fiscal year 2021: -$81.88 million | Fiscal year 2020: -$27.81 million | Fiscal year 2020: -$32.1 thousand | Fiscal year 2019: -$34.05 million | Fiscal year 2019: -$32.8 thousand | Fiscal year 2018: -$35.0 thousand.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: